XL413 (BMS-863233) demonstrated potent CDC7-dependent cell-cycle arrest and in vivo tumor growth inhibition in preclinical studies; however, both clinical trials that were initiated have since been terminated (NCT00838890 NCT00886782; ref. 18). The gene discussed is CDC7; the disease is neoplasm.